Security key
140755208
TVARDI THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (CARA)
CUSIP: 140755208
Q4 2025 13F Holders as of 31 Dec 2025
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 132
- Total 13F value
- $568
- Share change
- -22,033
- SEC-reported price per share
- $4.33
- Number of holders
- 3
- Value change
- -$861,996
- Number of buys
- 1
- Number of sells
- 6
- Shares outstanding
- 9,346,119
Holder snapshot
6 signals
Security identity
1 source field
Report period
Q4 2025
Institutions
3
Top holders
3
CARA full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q1 2026
Previous quarter: Q3 2025
Tvardi Therapeutics, Inc. SEC filings
Tvardi Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 140755208
Recent filing periods:
Ownership snapshot
Top reported holders of CARA - TVARDI THERAPEUTICS, INC. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Sporos Bioventures LLC
Disclosed value leader
Slate Path Capital LP
Comparable rows
15/15
Latest evidence
31 Dec 2025
13D/G
13F
3/4/5
Lead comparable stake: 9%
13D/G row: Sporos Bioventures LLC
Showing 1-6 of 15 holder rows.
Quick read
Sporos Bioventures LLC leads the comparable SEC ownership view at 9%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Comparable ownership
Top 5
Sporos Bioventures LLC
9%
Solas Tvardi Sidecar LLC
8.1%
Slate Path Capital LP
7.5%
David J. Tweardy
7%
Ronald A. DePinho
4.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Sporos Bioventures LLC |
13D/G
|
9%
|
$19,544,812
837,636 shares
|
$0 | 15 Apr 2025 |
| Solas Tvardi Sidecar LLC |
13D/G
|
8.1%
|
$4,050,047
761,287 shares
|
$0 | 15 Apr 2025 |
| Slate Path Capital LP |
13F
13D/G
Company
|
7.5%
from 13D/G
|
$27,439,478
704,118 shares
|
— | 30 Sep 2025 |
| David J. Tweardy |
13D/G
|
7%
|
$3,470,757
652,398 shares
|
$0 | 15 Apr 2025 |
| Ronald A. DePinho |
13D/G
|
4.5%
|
$1,939,164
426,190 shares
|
$0 | 31 Dec 2025 |
| Samuel D. Tweardy |
13D/G
|
3.4%
|
$7,365,343
315,658 shares
|
-$14,730,686 | 07 Jul 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
3
Shares
132
Rows available
3
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
8
Q4 2025 holders
3
Holder diff
-5
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 value | Q4 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend